MDUFMA II Should Address Pre-IDE Process, Cycle Goals – Stakeholders
This article was originally published in The Gray Sheet
Executive Summary
FDA should work to improve the process by which companies and the agency negotiate clinical trial designs, several participants argued at the third annual MDUFMA stakeholder meeting Nov. 17